New therapeutic effects of cilostazol in patients with ischemic disorders.
The objective of the present review is to analyze the existing data about the therapeutic effects of CIL, with the purpose of providing practical indications about this topic for the management of subjects affected by ischemic disorders. PMID: 26156267 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - July 11, 2015 Category: Drugs & Pharmacology Authors: Biscetti F, Ferraccioli G, Flex A Tags: Curr Vasc Pharmacol Source Type: research

The current role of liraglutide in the pharmacotherapy of obesity.
CONCLUSION: Liraglutide 3.0 mg appears to be an effective adjunct to a comprehensive lifestyle intervention to achieve weight reduction and treat obesity-related comorbidities. PMID: 26074046 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - June 15, 2015 Category: Drugs & Pharmacology Authors: Christou GA, Katsiki N, Kiortsis DN Tags: Curr Vasc Pharmacol Source Type: research

NON-VITAMIN ORAL ANTICOAGULANTS (NOACs) A review of clinical management and laboratory issues.
The objective of this review is to provide the practitioner with a comprehensive, balanced and contemporary view of these drugs and their applications. More specifically, it will focus on the evidence base for their licences, use in clinical practice (such as in renal dysfunction, orthopaedic surgery, atrial fibrillation, and venous thromboembolism, and the effects of co-medications), responses to actual or perceived haemorrhage, and the role of the laboratory. PMID: 26059459 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - June 9, 2015 Category: Drugs & Pharmacology Authors: Blann A Tags: Curr Vasc Pharmacol Source Type: research

Protective Role of Diabetes Mellitus on Abdominal Aortic Aneurysm Pathogenesis: myth or reality?
Abstract An inverse association between diabetes mellitus (DM) and abdominal aortic aneurysm (AAA) risk have been reported. Apart from a lower AAA prevalence among patients with vs without DM, there are data showing that DM may exert a protective role on aneurysmal growth in patients with small AAAs, thus decreasing the risk of rupture. As atherosclerosis has almost the same risk factors as aneurysms, the decreased AAA prevalence in patients with DM may indicate that atherosclerosis is an associated feature and not a cause of the aneurysms. Alternatively, DM may be associated with factors that influence AAA format...
Source: Current Vascular Pharmacology - May 29, 2015 Category: Drugs & Pharmacology Authors: Radak D, Tanaskovic S, Katsiki N, Isenovic ER Tags: Curr Vasc Pharmacol Source Type: research

Editorial: is ischemic stroke an inflammatory disease?
PMID: 25980650 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - May 22, 2015 Category: Drugs & Pharmacology Authors: Garibotto V, Pende A, Montecucco F Tags: Curr Vasc Pharmacol Source Type: research

Editorial: effect of statins on rates of long-term cardiovascular events and restenosis following carotid endarterectomy.
PMID: 25980651 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - May 22, 2015 Category: Drugs & Pharmacology Authors: Athyros VG, Katsiki N, Karagiannis A, Radak D Tags: Curr Vasc Pharmacol Source Type: research

Editorial: oxidative stress in pathophysiological conditions.
PMID: 25980652 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - May 22, 2015 Category: Drugs & Pharmacology Authors: Obradovic M, Bogdanovic N, Radak D, Isenovic ER Tags: Curr Vasc Pharmacol Source Type: research

Adherence to Mediterranean diet offers an additive protection over the use of statin therapy: results from the ATTICA study (2002-2012).
CONCLUSION: Adherence to Mediterranean diet confers a considerable reduction in CVD risk, independently of gender, age, family history of CVD, diabetes mellitus, smoking status, hypertension and physical activity status. Therefore, CVD prevention strategies should involve the implementation of a Mediterranean diet in both the general population and patients on a statin. PMID: 25877292 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 16, 2015 Category: Drugs & Pharmacology Authors: Panagiotakos DB, Georgousopoulou EN, Georgiopoulos GA, Pitsavos C, Chrysohoou C, Skoumas I, Ntertimani M, Laskaris A, Papadimitriou L, Tousoulis D, Stefanadis C Tags: Curr Vasc Pharmacol Source Type: research

Diabetes Mellitus in Patients Presenting with Cardiovascular Events: Descriptive Analysis from a Tertiary Heart Hospital Over a 22-year Period.
CONCLUSIONS: DM remains a healthcare challenge in Qatar. Although the admission rate of diabetic patients is increasing at the HH, the mortality rate is decreasing. The use of evidence-based medication is still far from the guideline recommendation; however, it has substantially improved. The lack of evidence-based CVD medications in diabetic patients was associated with an increased mortality up to 4-fold in the HH. Moreover, there is a need to enhance public awareness regarding CVD risk factors and DM through education programs for the adoption of healthier lifestyles and nutrition. Great efforts are needed for more effi...
Source: Current Vascular Pharmacology - March 31, 2015 Category: Drugs & Pharmacology Authors: El-Menyar A, Al-Thani H, Mekkodathil A, Mohammed S, Singh R, AlBinAli H, Suwaidi JA Tags: Curr Vasc Pharmacol Source Type: research

Is targeting microRNAs the philosopher's stone for vascular disease?
Abstract MicroRNAs (miRs) are small non-coding regulatory RNAs that control gene expression. They are involved in the pathogenesis of several diseases, including vascular and cardiac diseases. Their involvement is related to alterations of lipid metabolism, endothelial dysfunction, vascular smooth muscle cell phenotype, atherosclerosis-related low-grade inflammation of the arteries, cardiac hypertrophy or remodelling and heart failure. The manipulation of miRs may eventually be used to prevent or treat vascular or cardiac disease. Available drugs (some statins and renin-angiotensin-system inhibitors, alone or in c...
Source: Current Vascular Pharmacology - March 31, 2015 Category: Drugs & Pharmacology Authors: Athyros VG, Katsiki N, Karagiannis A Tags: Curr Vasc Pharmacol Source Type: research

Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
CONCLUSION: The clinical efficacy and safety of the generic CB is similar to that of the innovator CHS salt, thus, it can be routinely used in the secondary prevention of atherothrombotic events for a period of at least 6 months. (Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence, SCIENCE study Clinical Trials.gov Identifier: NCT02126982). PMID: 25782408 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 16, 2015 Category: Drugs & Pharmacology Authors: Ntalas IV, Kalantzi KI, Tsoumani ME, Vakalis I, Vasilakopoulos V, Vardakis C, Vemmos K, Voukelatou M, Giannakoulas G, Giatrakos I, Giogiakas V, Goumas G, Dimoulis N, Draganigos A, Efthimiadis I, Thoma M, Kazakos E, Kipouridis N, Konstantinou S, Milionis H Tags: Curr Vasc Pharmacol Source Type: research

Editorial: measuring myocyte oxidative stress and targeting cytokines to evaluate inflammatory response and cardiac repair after myocardial infarction.
PMID: 25751417 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 13, 2015 Category: Drugs & Pharmacology Authors: Fineschi V Tags: Curr Vasc Pharmacol Source Type: research

eBook Review (Review of The Bentham e-Book entitled "Anti-angiogenesis drug discovery and development- Volume 2" edited by Atta-ur-Rahman and M Iqbal Choudhary).
eBook Review (Review of The Bentham e-Book entitled "Anti-angiogenesis drug discovery and development- Volume 2" edited by Atta-ur-Rahman and M Iqbal Choudhary). Curr Vasc Pharmacol. 2015;13(1):141 Authors: Katsiki N PMID: 25751418 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 13, 2015 Category: Drugs & Pharmacology Authors: Katsiki N Tags: Curr Vasc Pharmacol Source Type: research

Oxidative Stress in Pathophysiological Conditions.
PMID: 25760442 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 11, 2015 Category: Drugs & Pharmacology Authors: Obradovic M, Bogdanovic N, Radak D, Isenovic ER Tags: Curr Vasc Pharmacol Source Type: research

Financial Crisis, Drug Compliance and Cardiovascular Health-the GREECS Case?
PMID: 25760443 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 11, 2015 Category: Drugs & Pharmacology Authors: G Panayiotou A Tags: Curr Vasc Pharmacol Source Type: research

Old And New Oral Anticoagulants In Management Of Atrial Fibrillation: A Double-Edged Sword For Women.
Abstract Atrial fibrillation (AF), one of the most prevalent supra-ventricular arrhythmia in adults, is related to a substantial increase in the risk of thromboembolic events requiring tailored preventive strategy. In AF, antithrombotic therapy should be individualized according to a careful decision-making process, taking in account the likely concomitant presence of risk factors for stroke and bleeding. Anticoagulation management is particularly challenging in women with AF, to the extent that female sex is incorporated in commonly used stratification schemes for both thromboembolic and bleeding risk evaluation....
Source: Current Vascular Pharmacology - February 16, 2015 Category: Drugs & Pharmacology Authors: Stefania B, Valeria R, Marco P, Laura N, Patrizia F, Flavia F Tags: Curr Vasc Pharmacol Source Type: research

Heart Failure Models: Traditional and Novel Therapy.
Abstract Cardiovascular disease (CVD) is among the most major causes of morbidity and mortality worldwide. Great progress has been made in the management of CVD which has been influenced by the use of experimental animal models. These models provided information at cellular and molecular levels and allowed the development of treatment strategies. CVD models have been developed in many species, including large animals (e.g. pigs and dogs) and small animals (e.g. rats and mice). Although, no model can solely reproduce clinical HF, simulations of heart failure (HF) are available to experimentally tackle certain queri...
Source: Current Vascular Pharmacology - February 12, 2015 Category: Drugs & Pharmacology Authors: Haidara MA, Assiri AS, Z Yassin H, Ammar HI, Obradovic MM, Isenovic ER Tags: Curr Vasc Pharmacol Source Type: research

Microcirculation in Hypertension: An Update on Clinical Significance and Therapy.
Abstract Essential hypertension is closely related to alterations of the microcirculation as evidenced by increased media-to-lumen ratio of small resistance arteries and capillary rarefaction. It has been proposed that microvasculature alterations can further deteriorate target organ damage under the influence of increased hemodynamic load in hypertension. More than a decade ago, small artery structure was found to be the most potent predictor of cardiovascular events in essential or secondary hypertension. Amelioration of resistance vessel structure by antihypertensive drugs showed a clear benefit when patients w...
Source: Current Vascular Pharmacology - February 5, 2015 Category: Drugs & Pharmacology Authors: Tsioufis C, Dimitriadis K, Katsiki N, Tousoulis D Tags: Curr Vasc Pharmacol Source Type: research

Effects of Kallistatin on Oxidative Stress and Inflammation on Renal Ischemia-Reperfusion Injury in Mice.
In this study, investigative research is used to draw results on the administration of human KS on kidney response conducted within a mouse model of IRI. Materials and methods: BALB/c mice were used and given 30 min ischemia that was injected into the kidney which was followed with 24 h reperfusion. The human KS gene contained within an adenoviral vector was injected intravenously 30 min before reperfusion and 12h after reperfusion. Analyses illustrated what impact KS had on renal IRI in realtion to tubular necrosis, apoptotic cell death, inflammatory cytokines, renal function, and inflammatory cell infiltration. Results: ...
Source: Current Vascular Pharmacology - February 4, 2015 Category: Drugs & Pharmacology Authors: Zhou S, Sun Y, Zhuang Y, Zhao W, Chen Y, Jiang B, Guo C, Zhang Z, Peng HU, Chen Y Tags: Curr Vasc Pharmacol Source Type: research

Drugs and Rhabdomyolysis: from Liver to kidney.
Abstract Rhabdomyolysis is a syndrome due to a damage of skeletal muscle and the leakage of intracellular contents into the extracellular fluid and the circulation. Several causes may induce rhabdomyolysis and the major one is the crush syndrome. Most cases of non-traumatic rhabdomyolysis are related to drugs. Many molecules are subject to hepatic metabolism and the concomitant use of drugs, as statins, with other medications acting as substrates of the same isoenzymes can interact and increase the risk of myopathy. Subclinical rise of creatine kinase may be expression of rhabdomyolysis that can range even to medi...
Source: Current Vascular Pharmacology - January 30, 2015 Category: Drugs & Pharmacology Authors: Barbano B, Sardo L, Gasperini ML, Gigante A, Liberatori M, Giraldi G DL, Di Mario F, Dorelli B, Amoroso A, Cianci R Tags: Curr Vasc Pharmacol Source Type: research

Pharmacogenetics and Statin Treatment: Reality or Theory?
Abstract Pharmacogenetics investigates heritable genetic polymorphisms that can effect responses to drug therapy. The main application of pharmacogenetics is genotype-guided dosing of medications and genotype-selection of treatment with the highest efficacy and lowest risk of adverse effects. Cardiovascular disease (CVD) is the leading cause of mortality and morbidity globally. Dyslipidemia is one of the classical risk factors for developing CVD. 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors called statins are the cornerstones in dyslipidemia treatment. However, there is a broad variation in i...
Source: Current Vascular Pharmacology - January 30, 2015 Category: Drugs & Pharmacology Authors: Bousoula E, Kolovou V, Perrea D, Kolovou G Tags: Curr Vasc Pharmacol Source Type: research

MicroRNA-10b Induces Vascular Muscle Cell Proliferation through Akt Pathway by Targeting TIP30.
Abstract Abnormal proliferation of vascular smooth muscle cells (VSMCs) contributes significantly to the pathogenesis of atherosclerosis. MiR-10b has recently emerged as critical mediator in regulating cell proliferation in many diseases.. In our study, miR-10b expression was significantly up-regulated in VSMCs isolated from atherosclerotic plaques, as well as in PDGF-stimulated VSMCs. Overexpression of miR-10b significantly promoted VSMCs cell proliferation of VSMCs. Furthermore, we identified the Tat-interacting protein 30 (TIP30) as a direct target gene of miR-10b. TIP30 was down-regulated in VSMCs isolated fro...
Source: Current Vascular Pharmacology - January 22, 2015 Category: Drugs & Pharmacology Authors: Yu X, Li Z, Wu WK Tags: Curr Vasc Pharmacol Source Type: research

Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment.
Conclusions: Only 2 of 4 Rotterdam phenotypes, identical with those of the classic PCOS definition, have excess cardiometabolic risk. These need to be treated to prevent CVD events. PMID: 25600030 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 20, 2015 Category: Drugs & Pharmacology Authors: Daskalopoulos G, Karkanaki A, Piouka A, Prapas N, Panidis D, Gkeleris P, Athyros VG Tags: Curr Vasc Pharmacol Source Type: research

Lower financial status and adherence to medication determines 10-year (2004-2014) all-cause mortality and risk for Acute Coronary Syndrome incidence among cardiac patients: the GREECS Study.
Abstract Background: Financial status has been considered as an important health determinant and has been associated with compliance to healthier lifestyle habits, medical treatment and increased prevalence of mental disorders. The aim of this work was to evaluate the association between financial status, patient adherence to medication, 10-year all-cause mortality and risk for Acute Coronary Syndrome (ACS), in a Greek sample of cardiac patients. Methods: From October 2003-September 2004 a sample of 2,172 consecutive ACS patients from 6 hospitals was enrolled. In 2013-14, the 10-year follow-up was performed in 1,9...
Source: Current Vascular Pharmacology - January 19, 2015 Category: Drugs & Pharmacology Authors: Notara V, Panagiotakos DB, Pitsavos C, Kogias Y, Stravopodis P, Papanagnou G, Zombolos S, Mantas Y, Stefanadis C Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular Risk Factors In Chronic Inflammatory Rheumatic Diseases: Modern Assessment And Diagnosis.
Abstract The current view is that systemic inflammation, which is specific to all chronic inflammatory rheumatic diseases (CIRD), accelerates atherogenesis; this hypothesis is supported by the high cardiovascular (CV) morbidity and mortality rates and the high prevalence of all atherosclerosis stages and complications in CIRD patients. The assessment of traditional CV risk factors underestimates the actual risk in patients with CIRD. A comprehensive evaluation and follow-up of both traditional and non-traditional CV risk factors, as well as the correct classification of risk reduction categories are necessary. Ima...
Source: Current Vascular Pharmacology - January 4, 2015 Category: Drugs & Pharmacology Authors: Rezuș E, Floria M, Grigoriu A, Tamba BI Tags: Curr Vasc Pharmacol Source Type: research

Recent Advances in Optimal Adjunctive Antithrombotic Therapy in STEMI Patients Undergoing Primary Angioplasty: an Overview.
Abstract There has been a considerable effort to improve adjunctive antithrombotic therapies to reperfusion strategies in the treatment of ST-segment elevation Myocardial Infarction (STEMI). Therefore, the aim of this article is to provide a critical and updated overview of recent advances on adjunctive antithrombotic therapies in patients undergoing primary angioplasty for STEMI. Due to very low costs, early Unfractionated Heparin (UFH) plus additional periprocedural administration should still be regarded as the gold standard in antithrombotic therapy, whereas subsequent subcutaneous administration of Low Molecu...
Source: Current Vascular Pharmacology - December 28, 2014 Category: Drugs & Pharmacology Authors: De Luca G, Suryapranata H Tags: Curr Vasc Pharmacol Source Type: research

Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?).
PMID: 25516014 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 19, 2014 Category: Drugs & Pharmacology Authors: Athyros VG, Katsiki N, Karagiannis A Tags: Curr Vasc Pharmacol Source Type: research

Renalase Is Removed By Kidneys And During Dialysis - Excess Related To CKD Complications?
Abstract Background: The most common complications of chronic kidney disease (CKD) are hypertension and cardiovascular (CV) disorders. Renalase is produced and relased by the kidney and also cardiomyocytes. Renalase deficiency was claimed to be responsible for hypertension and CV complication in CKD. There are contradictory data about serum renalase becouse of low activity and high levels revealed in hypertensive patients with CKD. We assessed serum renalase concentration in objects with CKD after one-side and both-side nephrectomy (on haemodialysis [HD]), or haemodiafiltration (HDF), in urine and ultrafiltrate in...
Source: Current Vascular Pharmacology - December 17, 2014 Category: Drugs & Pharmacology Authors: Malyszko J, Koc-Zorawska E, Zorawski M, Kozminski P, Zbroch E, Rysz J, Banach M, Malyszko JS Tags: Curr Vasc Pharmacol Source Type: research

Novel microRNAs as Putative Therapeutic Targets in Cardiovascular Diseases.
PMID: 25515857 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 17, 2014 Category: Drugs & Pharmacology Authors: Karapetsas A, Tokamani M, Kolettas E, Sandaltzopoulos R Tags: Curr Vasc Pharmacol Source Type: research

Pleiotropic Effects of Statin in Therapy in Heart Failure: A Review.
Abstract Clinical trials demonstrated that statin therapy is associated with a significant reduction in cardiovascular morbidity and mortality when used for either primary or secondary prevention of cardiovascular events. Several studies have shown that statins, having an important effect in the prevention of acute coronary syndromes, are also able to prevent heart failure (HF) in patients with coronary artery disease. This review summarizes the experimental and clinical evidence regarding the role of statins in the management of HF. PMID: 25440594 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - November 27, 2014 Category: Drugs & Pharmacology Authors: Correale M, Abruzzese S, A Greco C, Concilio M, Di Biase M, D Brunetti N Tags: Curr Vasc Pharmacol Source Type: research

Platelet Inhibition Agents: Current and Future P2Y12 Receptor Antagonists.
Abstract Percutaneous coronary intervention is widely used to reduce the risk of death or cardiovascular events in patients with acute coronary syndromes. Dual antiplatelet treatment with aspirin and clopidogrel has become routine practice to prevent thrombotic events after coronary surgery. Despite advances of significant reduction of thrombotic complications in this adjunctive therapy, major adverse cardiovascular events still occur, suggesting the need for development of novel antiplatelet agents that act as superior alternatives to current standard regimen. Recently developed antiplatelet agents (prasugrel, ti...
Source: Current Vascular Pharmacology - November 27, 2014 Category: Drugs & Pharmacology Authors: Tang J, Li MP, Zhou HH, Chen XP Tags: Curr Vasc Pharmacol Source Type: research

Is There a Role for Cortisol in the Accumulation of Lipids in the Intima a Crucial Step of Atherogenesis?
ez JR Abstract Accumulation of lipids in the intima is the initial and crucial step in atherogenesis, but, this step is not always synonymous with atherogenesis. The factors that trigger the mechanisms modulating lipid accumulation in the vessel wall and in the subsequent development of atherosclerotic plaque remain unclear. In this review we evaluate whether atherogenesis is modulated by cortisol, the end hormone of the stress-related anti-inflammatory system. The amount of accumulated lipids in the intima depends on the balance between the penetration and efflux of cholesterol from the artery wall. We assess whe...
Source: Current Vascular Pharmacology - November 27, 2014 Category: Drugs & Pharmacology Authors: Fantidis P, Sánchez E, Tarhini I, Kahan I, Pineda T, Corrales JA, Gonzalez JR Tags: Curr Vasc Pharmacol Source Type: research

A Systematic Review on Levosimendan in Paediatric Patients.
Abstract Levosimendan is a calcium-sensitizing agent that improves cardiac function, hemodynamic performance, and survival in critically ill adult patient. Few data exist on its off-label use in paediatric patients. We therefore performed a systematic review updated in September 2013 of all the published articles describing the use of levosimendan in paediatric patients. We identified 24 studies published in the period 2004-2013 that included a total of 623 patients, the largest one being a case series of 293 patients. Most of the patients underwent cardiac surgery, other settings consisting of chronic heart failu...
Source: Current Vascular Pharmacology - November 27, 2014 Category: Drugs & Pharmacology Authors: Simona S, Paolo S, Maria Luisa A, Roberto D, Giovanni L, Alberto Z Tags: Curr Vasc Pharmacol Source Type: research

Effect of Non-antihypertensive Drugs on Endothelial Function in Hypertensive Subjects Evaluated by Flow-mediated Vasodilation.
Abstract Hypertension (HTN) is a major risk factor for atherosclerosis. Flow-mediated vasodilation (FMD) is an ultrasonic method used to evaluate endothelial function, which is associated with HTN and related complications. We summarized clinical trials focusing on the effects of non-antihypertensive drugs on endothelial function, as evaluated by FMD, in patients with HTN. Hypercholesterolemic patients with HTN who used the cholesterol-lowering drugs HMG-CoA reductase inhibitors (statins) had improved FMD with a reduction in cholesterol levels and no significant change in blood pressure (BP). Non-diabetic patients...
Source: Current Vascular Pharmacology - November 27, 2014 Category: Drugs & Pharmacology Authors: Miyamoto M, Kotani K, Taniguchi N Tags: Curr Vasc Pharmacol Source Type: research

Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we kill Two Birds with One Stone?
Abstract Heart failure with preserved ejection fraction (HFpEF). Arterial hypertension (AH), arterial stiffness (AS), older age, and female gender are the main determinants of HFpEF, but several cardiac or extra-cardiac pathologies are also possible causes. The combined ventricular-vascular stiffening (abnormal left atrium-left ventricle coupling related to AS) is the main contributor of the increased prevalence of HFpEF in elderly persons, particularly elderly women, and in younger persons with AH. The hospitalization and mortality rates of HFpEF are similar to those of heart failure with reduced EF (HFrEF). Howe...
Source: Current Vascular Pharmacology - November 26, 2014 Category: Drugs & Pharmacology Authors: Athyros VG, Pagourelias ED, Gossios TD, Vasilikos VG Tags: Curr Vasc Pharmacol Source Type: research

Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease.
In conclusion, GLP-1 receptor agonists and DPP-4 inhibitors appear to hold promise in patients with NAFLD but larger controlled studies with histological and clinical endpoints are needed to evaluate their effects in this population. PMID: 25412688 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - November 20, 2014 Category: Drugs & Pharmacology Authors: Nakouti T, Karagiannis AK, Tziomalos K, Cholongitas E Tags: Curr Vasc Pharmacol Source Type: research

Tenofovir-Related Nephropathies in HIV-Infected Patients.
CONCLUSION: This study highlights that TDF nephrotoxicity is a widely frequent but reversible form of renal damage with preferentially proximal tubular dysfunction. We suggest that all patients at the time of HIV diagnosis should carry out a screening for kidney disease with eGFR assessment, proteinuria, and urine analysis. PMID: 25412689 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - November 20, 2014 Category: Drugs & Pharmacology Authors: Lai S, Mariotti A, Lai C, Testorio M, Carta M, Innico G, Frassetti N, Mangiulli M, D'Angelo A, Russo GE Tags: Curr Vasc Pharmacol Source Type: research

MicroRNA-136 Promotes Vascular Muscle Cell Proliferation Through the ERK1/2 Pathway by Targeting PPP2R2A in Atherosclerosis.
Abstract Aberrant proliferation of vascular smooth muscle cells [VSMCs] is implicated in the pathogenesis of vascular pathologies such as atherosclerosis and restenosis. Accumulating evidences have revealed that microRNAs are involved in cell proliferation in various pathological conditions. In the present study, we showed that miR-136 was up regulated in human coronary atherosclerotic plaques when compared with normal coronary artery tissues. Moreover, miR-136 levels were up regulated in proliferative vascular smooth muscle cells induced by platelet-derived growth factor [PDGF] or serum. In cultured VSMCs, over e...
Source: Current Vascular Pharmacology - November 17, 2014 Category: Drugs & Pharmacology Authors: Zhang CF, Kang K, Li XM, Xie BD Tags: Curr Vasc Pharmacol Source Type: research

Dyslipidemia, Vascular Atheroma and Statins.
Abstract Dyslipidemia plays an important role in the initiation, progression of atherosclerotic coronary artery disease. However, regression of atherosclerotic atheroma by introducing lipid lowering agents is not fully understood but looks promising. More questions still need to be answered in terms of the modality of assessment, time course of changes and its documentation, whether plaque progression or regression assessed by imaging one arterial tree reflects a uniform effect throughout all arterial territories and whether atheroma regression is a therapeutic goal. Furthermore, which statins to use, as monothera...
Source: Current Vascular Pharmacology - October 29, 2014 Category: Drugs & Pharmacology Authors: Abuzaid A, El-Menyar A Tags: Curr Vasc Pharmacol Source Type: research

Effect of Statins on rates of Long-Term Cardiovascular Events and Restenosis Following Carotid Endarterectomy.
PMID: 25322832 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 17, 2014 Category: Drugs & Pharmacology Authors: Athyros VG, Katsiki N, Karagiannis A, Radak D Tags: Curr Vasc Pharmacol Source Type: research

Persistent Elevation of Blood Pressure in Children and Adolescents is Associated with Arterial Hypertension and Premature Atherosclerosis in Adults. Is it Possible to Reverse This?
PMID: 25322833 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 17, 2014 Category: Drugs & Pharmacology Authors: Athyros VG, Katsiki N, Karagiannis A Tags: Curr Vasc Pharmacol Source Type: research

Relation between the Change in Mean Platelet Volume and Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Intervention.
Abstract We aimed to determine the association between the change in mean platelet volume (MPV) over time and aspirin/ clopidogrel resistance in patients undergoing percutaneous coronary intervention (PCI). The MPV and platelet function were analysed in 302 patients who underwent PCI. MPV changes were associated with increased aspirin reaction units (ARU, r = 0.114; P = 0.047), increased P2Y12 reaction units (PRU, r = 0.193; P = 0.001), and decreased P2Y12% inhibition (PI%, r = - 0.273; P
Source: Current Vascular Pharmacology - October 17, 2014 Category: Drugs & Pharmacology Authors: Koh YY, Ho Kim H, Choi DH, Lee YM, Ki YJ, Kang SH, Park G, Chung JW, Chang KS, Hong SP Tags: Curr Vasc Pharmacol Source Type: research

Phenomics of Vascular Disease: the systematic approach to the combination therapy.
Abstract Vascular diseases are usually caused by multifactorial pathogeneses involving genetic and environmental factors. Our current understanding of vascular disease is, however, based on the focused genotype/phenotype studies driven by the "one-gene/one-phenotype" hypothesis. Drugs with "pure target" at individual molecules involved in the pathophysiological pathways are the mainstream of current clinical treatments and the basis of combination therapy of vascular diseases. Recently, the combination of genomics, proteomics, and metabolomics has unraveled the etiology and pathophysiology of v...
Source: Current Vascular Pharmacology - October 14, 2014 Category: Drugs & Pharmacology Authors: Han Y, Li L, Zhang Y, Yuan H, Ye L, Zhao J, Duan DD Tags: Curr Vasc Pharmacol Source Type: research

Coffee: A Selected Overview of Beneficial or Harmful Effects on the Cardiovascular System?
Abstract With a history that began in 800 A.D., coffee is the most popular drink known and as a result, the issues regarding its physiologic effects deserve attention. Maintaining alertness is a well-known benefit and in addition, the cardiovascular (CV) effects of the active compounds, which include polyphenols and caffeine, must be considered. Genetics are relevant and where slow caffeine metabolism is inherent, the risk of nonfatal myocardial (MI) has been shown to be increased. Overall risk for coronary heart disease (CHD) is not supported and unless there is excessive intake, congestive heart failure (CHF) is...
Source: Current Vascular Pharmacology - October 2, 2014 Category: Drugs & Pharmacology Authors: Whayne Jr TF Tags: Curr Vasc Pharmacol Source Type: research

Not Simply a Matter of Fish Intake.
Abstract Background and aims: Recent findings have highlighted enhanced fish consumption as a potential measure to increase intake of healthy fatty acids, particularly omega-3. The generalizability of this recommendation, however, may fall short by differences in fish species and cooking techniques. Hence, we investigated how these 2 variables affect the lipid content in fish flesh. Methods and Results: Nine species of freshwater, deep sea or shore fish were grilled, steamed or fried with or without the addition of soybean oil, olive oil or butter. The lipid composition was analysed and a significant difference wa...
Source: Current Vascular Pharmacology - October 2, 2014 Category: Drugs & Pharmacology Authors: Scherr C, Figueiredo VN, Moura FA, Sposito AC Tags: Curr Vasc Pharmacol Source Type: research

Statin Potency, LDL Receptors and New Onset Diabetes.
PMID: 25135802 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - August 19, 2014 Category: Drugs & Pharmacology Authors: Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP Tags: Curr Vasc Pharmacol Source Type: research

Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies.
Abstract There is growing evidence that Rho-kinase contributes to cardiovascular disease, which has made Rho-kinase a target for the treatment of human diseases. To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic injury after surgery for subarachnoid hemorrhage (SAH). A number of pathological processes, in particular hemodynamic dysfunctions and inflammatory reactions, are thought to be related in the pathogenesis of delayed cerebral vasospasm and subsequent ischemic injury after SAH. This review focu...
Source: Current Vascular Pharmacology - June 13, 2014 Category: Drugs & Pharmacology Authors: Satoh SI, Ikegaki I, Kawasaki K, Asano T, Shibuya M Tags: Curr Vasc Pharmacol Source Type: research

Editorial: antithrombotic therapy: current and future clinical use.
PMID: 24846223 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Agnelli G Tags: Curr Vasc Pharmacol Source Type: research

Acute antithrombotic treatment of ischemic stroke.
Abstract Antithrombotic medication is a cornerstone of acute ischemic stroke treatment and secondary prevention. The efficacy of thrombolysis with alteplase in acute stroke has been demonstrated in several clinical trials. This safe and costeffective therapy has transformed the practice of stroke care and has led to subsequent trials of other antithrombotic medications for treatment of ischemic stroke in the acute phase. These antithrombotics include thrombolytic, antiplatelet and anticoagulant agents. While, no other medication has yet demonstrated adequate efficacy, our current and evolving understanding of infa...
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Alderazi YJ, Grotta JC Tags: Curr Vasc Pharmacol Source Type: research

Secondary prevention of atherothrombotic cerebrovascular events.
The objective of this review is to discuss effective interventions for optimal secondary prevention of atherosclerotic stroke. PMID: 24846225 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Paciaroni M Tags: Curr Vasc Pharmacol Source Type: research